Physician profile
Mark John Frilling
NPI 1326535139
$1,511.17
in general payments reported to CMS, 2019-2025
12 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $703 · 2024: $298 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $508.12 | 2023-2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Medtronic, INC. | $187.24 | 2022 | |
| Genzyme Corporation | $145.52 | 2023-2025 | |
| Stryker Corporation | $125.11 | 2023 | Latera, Clarifix Cryotherapy Device, Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $123.61 | 2023-2024 | Dupixent |
| Checkpoint Surgical, INC | $123.34 | 2023 | Checkpoint Stimulators |
| Glaxosmithkline, LLC. | $119.69 | 2023-2025 | Nucala |
| Regeneron Pharmaceuticals, INC. | $101.99 | 2025 | Dupixent |
| Acclarent, INC | $37.50 | 2023 | Acclarent Aera |
| Optinose US, INC. | $16.13 | 2023 | |
| Hikma Pharmaceuticals USA | $13.36 | 2024 | Ryaltris |
| Med-El Corporation | $9.56 | 2025 | Mi1250 Synchrony 2 Flexsoft, Bci 602 Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Frilling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.